Increased soluble serum markers caspase-cleaved cytokeratin-18, histones, and ST2 indicate apoptotic turnover and chronic immune response in COPD

Journal of Clinical Laboratory Analysis

Volumn 23, Issue 6, 2009, Pages 372-379

  Hacker, Stefan ^a,b   Lambers, Christopher ^a   Pollreisz, Andreas ^a   Hoetzenecker, Konrad ^a,b   Lichtenauer, Michael ^a,b   Mangold, Andreas ^a,b   Niederpold, Tina ^a,b   Hacker, Andreas ^a   Lang, György ^a   Dworschak, Martin ^a   Vukovich, Thomas ^a   Gerner, Christopher ^b,c   Klepetko, Walter ^a   Ankersmit, Hendrik Jan ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INSTITUTE FOR MICROELECTRONICS   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Apoptosis; COPD; Cytokeratin; GOLD; Immune system; Serum; Smoking

Indexed keywords

CASPASE; CYTOKERATIN 18; DNA FRAGMENT; HISTONE; INTERLEUKIN 1BETA CONVERTING ENZYME;

ADULT; APOPTOSIS; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PROTEIN CLEAVAGE;

APOPTOSIS; BIOLOGICAL MARKERS; CASPASES; DEMOGRAPHY; DNA; FEMALE; HISTONES; HUMANS; INTERLEUKIN-10; KERATIN-18; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, CELL SURFACE; SOLUBILITY;

EID: 73249129044     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20348     Document Type: Article

References (44)

1. Mannino DM. COPD: Epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 2002;121:121S-126S.
2. Higenbottam T, Clark TJ, Shipley MJ, Rose G. Lung function and symptoms of cigarette smokers related to tar yield and number of cigarettes smoked. Lancet 1980;1:409-411.
3. Hacker S, Lambers C, Hoetzenecker K, et al. Elevated HSP27, HSP70 and HSP90 alpha in chronic obstructive pulmonary disease: Markers for immune activation and tissue destruction. Clin Lab 2009;55:31-40.
4. Lambers C, Hacker S, Posch M, et al. T cell senescence and contraction of T cell repertoire diversity in patients with chronic obstructive pulmonary disease. Clin Exp Immunol 2009;155:466-475.
5. MacNee W. Oxidants/antioxidants and COPD. Chest 2000;117:303S-317S.
6. Hodge S, Hodge G, Scicchitano R, Reynolds PN, Holmes M. Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells. Immunol Cell Biol 2003;81:289-296.
7. Yokohori N, Aoshiba K, Nagai A. Increased levels of cell death and proliferation in alveolar wall cells in patients with pulmonary emphysema. Chest 2004;125:626-632.
8. Hodge S, Hodge G, Holmes M, Reynolds PN. Increased airway epithelial and T-cell apoptosis in COPD remains despite smoking cessation. Eur Respir J 2005;25:447-454.
9. Demedts IK, Demoor T, Bracke KR, Joos GF, Brusselle GG. Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema. Respir Res 2006;7:53.
10. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514-1519.
11. Takabatake N, Nakamura H, Inoue S, et al. Circulating levels of soluble Fas ligand and soluble Fas in patients with chronic obstructive pulmonary disease. Respir Med 2000;94:1215-1220.
12. Newton R, Holden NS, Catley MC, et al. Repression of inflammatory gene expression in human pulmonary epithelial cells by small-molecule IkappaB kinase inhibitors. J Pharmacol Exp Ther 2007;321:734-742.
13. Adlbrecht C, Hoetzenecker K, Posch M, et al. Elevated levels of interleukin-1beta-converting enzyme and caspase-cleaved cytokeratin-18 in acute myocardial infarction. Eur J Clin Invest 2007;37:372-380.
14. Soleiman A, Lukschal A, Hacker S, et al. Myocardial lipofuscin-laden lysosomes contain the apoptosis marker caspase-cleaved cytokeratin-18. Eur J Clin Invest 2008;38:708-712.
15. Roth GA, Krenn C, Brunner M, et al. Elevated serum levels of epithelial cell apoptosis-specific cytokeratin 18 neoepitope m30 in critically ill patients. Shock 2004;22:218-220.
16. Hetz H, Hoetzenecker K, Hacker S, et al. Caspase-cleaved cytokeratin 18 and 20 S proteasome in liver degeneration. J Clin Lab Anal 2007;21:277-281.
17. Szerafin T, Horvath A, Moser B, et al. Apoptosis-specific activation markers in on- versus off-pump coronary artery bypass graft (CABG) patients. Clin Lab 2006;52:255-261.
18. Martinez-Rumayor A, Camargo CA, Green SM, Baggish AL, O'Donoghue M, Januzzi JL. Soluble ST2 plasma concentrations predict 1-year mortality in acutely dyspneic emergency department patients with pulmonary disease. Am J Clin Pathol 2008;130:578-584.
19. Rehman SU, Mueller T, Januzzi Jr JL. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 2008;52:1458-1465.
20. Tajima S, Oshikawa K, Tominaga S, Sugiyama Y. The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest 2003;124:1206-1214.
21. Brunner M, Krenn C, Roth G, et al. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med 2004;30:1468-1473.
22. Szerafin T, Niederpold T, Mangold A, et al. Secretion of soluble ST2 - Possible explanation for systemic immunosuppression after heart surgery. Thorac Cardiovasc Surg 2009;57:25-29.
23. Szerafin T, Brunner M, Horvath A, et al. Soluble ST2 protein in cardiac surgery: A possible negative feedback loop to prevent uncontrolled inflammatory reactions. Clin Lab 2005;51:657-663.
24. Thornberry NA, Bull HG, Calaycay JR, et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 1992;356:768-774.
25. Kramer G, Erdal H, Mertens HJ, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 2004;64:1751-1756.
26. Zunino SJ, Singh MK, Bass J, Picker LJ. Immunodetection of histone epitopes correlates with early stages of apoptosis in activated human peripheral T lymphocytes. Am J Pathol 1996;149:653-663.
27. Kumar S. ICE-like proteases in apoptosis. Trends Biochem Sci 1995;20:198-202.
28. Trajkovic V, Sweet MJ, Xu D. T1/ST2 - An IL-1 receptor-like modulator of immune responses. Cytokine Growth Factor Rev 2004;15:87-95.
29. Kondo S, Kondo Y, Yin D, et al. Involvement of interleukin-1 beta-converting enzyme in apoptosis of bFGF-deprived murine aortic endothelial cells. FASEB J 1996;10:1192-1197.
30. Schumann RR, Belka C, Reuter D, et al. Lipopolysaccharide activates caspase-1 (interleukin-1-converting enzyme) in cultured monocytic and endothelial cells. Blood 1998;91:577-584.
31. Schaafsma HE, Ramaekers FC. Cytokeratin subtyping in normal and neoplastic epithelium: Basic principles and diagnostic applications. Pathol Annu 1994;29:21-62.
32. Caulin C, Salvesen GS, Oshima RG. Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J Cell Biol 1997;138:1379-1394.
33. Schutte B, Henfling M, Kolgen W, et al. Keratin 8/18 breakdown and reorganization during apoptosis. Exp Cell Res 2004;297:11-26.
34. Leers MP, Kolgen W, Bjorklund V, et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 1999;187:567-572.
35. Grumelli S, Corry DB, Song LZ, et al. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med 2004;1:e8.
36. de Waal Malefyt R, Haanen J, Spits H, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991;174:915-924.
37. Barksby HE, Lea SR, Preshaw PM, Taylor JJ. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin Exp Immunol 2007;149:217-225.
38. Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 2007;282:26369-26380.
39. Tajima S, Bando M, Ohno S, et al. ST2 gene induced by type 2 helper T cell (Th2) and proinflammatory cytokine stimuli may modulate lung injury and fibrosis. Exp Lung Res 2007;33:81-97.
40. Kopp EB, Medzhitov R. The Toll-receptor family and control of innate immunity. Curr Opin Immunol 1999;11:13-18.
41. Akira S, Takeda K, Kaisho T. Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675-680.
42. Greisman SE, Young EJ, Woodward WE. Mechanisms of endotoxin tolerance. IV. Specificity of the pyrogenic refractory state during continuous intravenous infusions of endotoxin. J Exp Med 1966;124:983-1000.
43. Nomura F, Akashi S, Sakao Y, et al. Cutting edge: Endotoxin tolerance in mouse peritoneal macrophages correlates with downregulation of surface toll-like receptor 4 expression. J Immunol 2000;164:3476-3479.
44. Brint EK, Xu D, Liu H, et al. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol 2004;5:373-379.